Results 101 to 110 of about 47,712 (207)

A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs [PDF]

, 2017
Background: Diabetes mellitus is a metabolic disorder defined by high blood glucose. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are a newer class of medications that offer potential 2 to 3 kg weight loss and a 1% to 1.5% decrease in A1c.
Beutel Darrow, Shelby L.
core   +1 more source

The Role of the Dietitian in Incretin-Based Obesity Therapies in Italy: Practical Clinical Challenges, Professional Clarity, and the Sarcopenic Obesity Perspective

Dietetics
Background: Incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonists, advance obesity treatment by promoting weight loss and lowering the ...
Daniela Ojeda-Mercado, Maurizio Fadda, Benedetta Beltrame, Martina Tosi, Amalia Bruno, Carmen Di Scala, Giancarlo Travaglia, Assunta Vitale, Rita Schiano di Cola, Stefano Boschetti, Federica Pessina, Roberta Jaccheri, Liisa Tolvanen   +12 more
doaj   +1 more source

Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance. [PDF]

, 2019
The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose ...
Chan, Luisa S, Chordia, Mahendra D, El Ouarrat, Dalila, Han, Andrew W, Jain, Mohit, Johnson, Andrew MF, Lee, Yun Sok, Mahmood, Nadir A, Ofrecio, Jachelle M, Olefsky, Jerrold M, Pan, Dongfeng, Riopel, Matthew, Ryan, Caitlin N, Watrous, Jeramie D, Wollam, Joshua, Xu, Yong-Jiang, Ying, Wei   +16 more
core   +1 more source

Revisiting food addiction in the era of GLP-1–based obesity pharmacotherapy via neural reward pathways linking feeding and substance use

Frontiers in Behavioral Neuroscience
Obesity rates, once thought to be on an inevitable rise with limited treatment options, have recently stabilized and begun to decline in the US, a trend that coincides with the increased use of GLP-1 receptor agonist medications for weight management ...
Richard M. O’Connor
doaj   +1 more source

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart

Pharmaceutics
Glucagon-like-peptide-1 receptor (GLP-1R) agonists are under development as new drugs to treat type 2 diabetes, liver disease, obesity and cardiovascular diseases. Some of these drugs are solely agonists of the GLP-1R.
Joachim Neumann, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +3 more
doaj   +1 more source

Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus

Journal of Pharmacy and Bioallied Sciences
Introduction: The goal of this study was to find out how SGLT2 inhibitors and GLP-1 receptor agonists help persons with Type 2 Diabetes Mellitus (T2DM) keep their blood sugar levels stable. Methodology: There were 120 people in the trial.
Ved Prakash, Sangeeta Gupta, Saumya Singh, Anurag Rawat, Amit Vasant Deshpande, Amrit Podder, Parth Jani   +6 more
doaj   +1 more source

CNS Control of Glucose Metabolism: Response to Environmental Challenges [PDF]

, 2013
Over the last 15 years, considerable work has accumulated to support the role of the CNS in regulating postprandial glucose levels. As discussed in the first section of this review, the CNS receives and integrates information from afferent neurons ...
Arble, Deanna M., Sandoval, Darleen A.
core   +1 more source

Insights into GLP-1 Receptor Activation with a Nonpeptide Agonist [PDF]

Biochemistry, 2020
Thomas F. Martinez, Joan Vaughan, Alan Saghatelian   +2 more
openaire   +4 more sources

GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis

Diabetology & Metabolic Syndrome
Previous studies have demonstrated an increased risk of developing Parkinson’s disease (PD) in patients with type 2 diabetes mellitus (T2DM), as well as more severe and rapid motor and non-motor deterioration in diabetic PD patients compared to their non-
Mohamed Mohsen Helal, Hala AbouShawareb, Omarfayez Hussein Abbas, Roaa Haddad, Youmna Zain, Ahmed S. A. Osman, Amr K. Hassan   +6 more
doaj   +1 more source

Increasing Postpartum Use of GLP-1 Receptor Agonists

JAMA
This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.
Bliddal, Mette, Nohmie, Gabra, Damkier, Per, Pottegård, Anton   +3 more
openaire   +3 more sources